Due to the dual inhibition of protein and enzymatic activity of both FLT3-ITD and Axl by gilteritinib and HHT, this combination may have an advantage to be used for FLT3-ITD AML relapsed from other inhibitor treatment. This evidence concerns the gene FLT3 and acute myeloid leukemia.